… of patients with cytomegalovirus disease from 60% (in controls) to 30% or less (in patients
… preemptive ganciclovir therapy); that is, we predicted that preemptive ganciclovir treatment …

… among patients with laboratory evidence of CMV infection [6] … that preemptive oral ganciclovir
therapy, when guided by qualitative polymerase chain reaction (qPCR) detection of CMV …

… infection at 12 months was significantly higher and there was a tendency for more patients
to develop CMV disease in the group receiving pre-emptive therapy (table II). Randomised …

… and ganciclovir have similar efficacy in preventing CMV disease … regarding valganciclovir
use in prophylaxis or preemption. … the efficacy of ganciclovir-based therapy against all others, …

… In this study, we evaluated the efficacy of a novel antigenemia-guided preemptive therapy
using a low initial dose of ganciclovir. CMV disease was documented in only one of the 40 …

… or preemptive therapy for the prevention of CMV disease in … preemptive therapy effective?
Are currently available tests for diagnosis of CMV infection reliable tools for preemptive therapy…

… were no episodes of CMV disease. Another report in … ganciclovir when each was used for
preemptive therapy [19]. There were no episodes of CMV disease or late-onset CMV disease …

… Although the aforementioned hypothesis remains to be proven, our data show that
antigenemia-guided preemptive therapy with valganciclovir and oral ganciclovir was effective not …

… [18] and our own ganciclovir dosing schedule for preemptive treatment, including costs for
therapeutic ganciclovir in about 10% of patients in each group as well as costs for surveillance …

… standard preemptive therapy in preventing CMV disease with … had CMV infection to receive
preemptive ganciclovir therapy … the two arms for the prevention of CMV disease after HSCT. …